This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
STXBP2 · Western blot design guide
STXBP2 Western Blot Planning Guide
Plan a STXBP2 Western blot around the catalog-observed 66.5 kDa band, image-backed PB9820 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
STXBP2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 66.5 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Breast | |
| Negative control | Cerebral cortex |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 66.5 kDa |
| ⓘ | Localization | Cell membrane / Cytolytic granule membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated STXBP2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Breast |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9820 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected STXBP2 Western Blot Band Size?
Use the product-observed 66.5 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 66.5 kDa | Matches the authoritative product WB observation. |
| 66.5 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected STXBP2 appearancePlan around 66.5 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 66.5 kDa; use this as the primary experimental expectation. |
| Calculated mass | 66.5 kDa from UniProt Q15833; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9820. |
| Situation | Likely cause | Next action |
|---|---|---|
| 66.5 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing STXBP2 band
PB9820 · STXBP2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for STXBP2 Western blot
🧪Use Breast as the first positive-control candidate and Cerebral cortex as the HPA Not detected negative candidate.
Positive control: Breast (Medium)
Negative control: Cerebral cortex (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for STXBP2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Fallopian tube | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced STXBP2 Western Blot Tips
Deeper troubleshooting and optimisation questions for STXBP2, answered from its protein features.
Which band should guide the blot?
Use 66.5 kDa, the observation attached to the authoritative PB9820 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 66.5 kDa expectation.
Which positive control should I start with?
Start with Breast, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Cerebral cortex as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for STXBP2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9820 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
STXBP2 Western Blot Reagents
Human/Mouse/Rat-reactive STXBP2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-STXBP2 Antibody Picoband®
Cat # PB9820
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q15833
- Human Protein Atlas — STXBP2
- PB9820 product record
- PMC8496341 — Case Report: Characterizing the Role of the STXBP2-R190C Monoallelic Mutation Found in a Patient With Hemophagocytic Syndrome and Langerhans Cell Histiocytosis (Frontiers in immunology, 2021)
- PMC7580532 — STXBP2-R190C Variant in a Patient With Neonatal Hemophagocytic Lymphohistiocytosis (HLH) and G6PD Deficiency Reveals a Critical Role of STXBP2 Domain 2 on Granule Exocytosis (Frontiers in immunology, 2020)
- PMC4641381 — Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains (Acta neuropathologica communications, 2015)